Spravato sales momentum underscores market potential for psychedelics, atai Life Sciences seen as key beneficiary
Summary
Sales of Johnson & Johnson (NYSE:JNJ)'s esketamine nasal spray Spravato grew sequentially in the second quarter, marking...
Sales of Johnson & Johnson (NYSE:JNJ)'s esketamine nasal spray Spravato grew sequentially in the second quarter, marking a positive sign for the broader psychedelics sector, according to Jefferies analysts. Spravato sales grew 29% quarter-over-quarter to $414 million worldwide.
Related Articles
What Is Considered a Good Stock Dividend? 3 Healthcare Stocks That Fit the Bill
JNJ
PositiveNANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1
JNJ
PositiveJ&J Painting Recognized with 2026 Consumer Choice Award for Painting Contractor in Waterloo
JNJ
Positive